Harbor Capital Advisors Inc. Sells 26,350 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Harbor Capital Advisors Inc. cut its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 2.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,001,388 shares of the company’s stock after selling 26,350 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in MiMedx Group were worth $9,633,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Bank of New York Mellon Corp increased its stake in MiMedx Group by 9.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 409,344 shares of the company’s stock valued at $2,837,000 after purchasing an additional 35,107 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of MiMedx Group by 909.0% during the second quarter. Victory Capital Management Inc. now owns 138,449 shares of the company’s stock valued at $959,000 after acquiring an additional 124,727 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in MiMedx Group in the 2nd quarter worth approximately $988,000. Quest Partners LLC bought a new position in MiMedx Group in the 2nd quarter valued at approximately $81,000. Finally, American Century Companies Inc. boosted its stake in MiMedx Group by 59.5% during the 2nd quarter. American Century Companies Inc. now owns 114,597 shares of the company’s stock valued at $794,000 after purchasing an additional 42,757 shares during the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Performance

MDXG stock traded down $0.23 on Friday, hitting $8.62. The company had a trading volume of 138,083 shares, compared to its average volume of 701,786. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of 15.67 and a beta of 1.96. The stock’s 50-day simple moving average is $8.95 and its 200 day simple moving average is $7.31.

Analysts Set New Price Targets

Separately, StockNews.com cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, MiMedx Group presently has an average rating of “Buy” and an average target price of $12.00.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.